We conducted an exploratory post hoc study that compared the cost effectiveness of five treatments for bulimia nervosa : 15 weeks of cognitive behavioral therapy (CB) followed by three monthly sessions, 16 weeks (Med16) and 24 weeks (Med24) of desipramine (¾300 mg/day), and CB combined with desipramine for those durations (Combo16 and Combo24).
We illustrate how a treatment's cost effectiveness varies according to when evaluation is done and how effectiveness and cost are defined.
At 32 weeks, Med16 appears the most cost-effective treatment, and Combo16 appears the least.
At 1 year, Med24 appears the most cost-effective treatment, and Combo16 appears the least.
Using this post hoc analysis as an example, we discuss the pitfalls and limitations of cost-effectiveness analysis of psychiatric treatments.
Mots-clés Pascal : Boulimie, Trouble comportement alimentaire, Traitement, Analyse avantage coût, Economie santé, Etude comparative, Thérapie comportementale, Thérapie cognitive, Chimiothérapie, Homme
Mots-clés Pascal anglais : Bulimia, Eating disorder, Treatment, Cost benefit analysis, Health economy, Comparative study, Behavior therapy, Cognitive therapy, Chemotherapy, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0529697
Code Inist : 002B18C01B. Création : 01/03/1996.